Citations (132)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (29)
James A Stockley, Robert A Stockley & Elizabeth Sapey. (2021) There is No Fast Track to Identify Fast Decliners in Alpha-1 Antitrypsin Deficiency by Spirometry: A Longitudinal Study of Repeated Measurements. International Journal of Chronic Obstructive Pulmonary Disease 16, pages 835-840.
Read now
Read now
Mark Quinn, Paul Ellis, Anita Pye & Alice M Turner. (2020) Obstacles to Early Diagnosis and Treatment of Alpha-1 Antitrypsin Deficiency: Current Perspectives. Therapeutics and Clinical Risk Management 16, pages 1243-1255.
Read now
Read now
Kylie B R Belchamber, Eloise M Walker, Robert A Stockley & Elizabeth Sapey. (2020) Monocytes and Macrophages in Alpha-1 Antitrypsin Deficiency. International Journal of Chronic Obstructive Pulmonary Disease 15, pages 3183-3192.
Read now
Read now
Franck F Rahaghi, Richard Monk, Viswanathan Ramakrishnan, Tatsiana Beiko & Charlie Strange. (2020) Alpha-1 Antitrypsin Augmentation Therapy Improves Survival in Severely Deficient Patients with Predicted FEV1 Between 10% and 60%: A Retrospective Analysis of the NHLBI Alpha-1 Antitrypsin Deficiency Registry. International Journal of Chronic Obstructive Pulmonary Disease 15, pages 3193-3199.
Read now
Read now
Kenneth R Chapman, Joanna Chorostowska-Wynimko, A Rembert Koczulla, Ilaria Ferrarotti & Noel G McElvaney. (2018) Alpha 1 antitrypsin to treat lung disease in alpha 1 antitrypsin deficiency: recent developments and clinical implications. International Journal of Chronic Obstructive Pulmonary Disease 13, pages 419-432.
Read now
Read now
Mario Cazzola, Paola Rogliani, Ermanno Puxeddu, Josuel Ora & Maria Gabriella Matera. (2018) An overview of the current management of chronic obstructive pulmonary disease: can we go beyond the GOLD recommendations?. Expert Review of Respiratory Medicine 12:1, pages 43-54.
Read now
Read now
David G Parr & Beatriz Lara. (2017) Clinical utility of alpha-1 proteinase inhibitor in the management of adult patients with severe alpha-1 antitrypsin deficiency: a review of the current literature. Drug Design, Development and Therapy 11, pages 2149-2162.
Read now
Read now
Jorge E. Lascano & Michael A. Campos. (2017) The important role of primary care providers in the detection of alpha-1 antitrypsin deficiency. Postgraduate Medicine 129:8, pages 889-895.
Read now
Read now
Ross G Edgar, Mitesh Patel, Susan Bayliss, Diana Crossley, Elizabeth Sapey & Alice M Turner. (2017) Treatment of lung disease in alpha-1 antitrypsin deficiency: a systematic review. International Journal of Chronic Obstructive Pulmonary Disease 12, pages 1295-1308.
Read now
Read now
Maria Paula Henao & Timothy J. Craig. (2016) Recent advances in understanding and treating COPD related to α1-antitrypsin deficiency. Expert Review of Respiratory Medicine 10:12, pages 1281-1294.
Read now
Read now
Joanna Chorostowska-Wynimko. (2016) Disease Modification in Emphysema Related to Alpha-1 Antitrypsin Deficiency. COPD: Journal of Chronic Obstructive Pulmonary Disease 13:6, pages 807-815.
Read now
Read now
Robert A Stockley, Ross G Edgar, Anilkumar Pillai & Alice M Turner. (2016) Individualized lung function trends in alpha-1-antitrypsin deficiency: a need for patience in order to provide patient centered management?. International Journal of Chronic Obstructive Pulmonary Disease 11, pages 1745-1756.
Read now
Read now
Sanjay H Chotirmall, Mazen Al-Alawi, Thomas McEnery & Noel G McElvaney. (2015) Alpha-1 proteinase inhibitors for the treatment of alpha-1 antitrypsin deficiency: safety, tolerability, and patient outcomes. Therapeutics and Clinical Risk Management 11, pages 143-151.
Read now
Read now
Katrin Milger, Lesca Miriam Holdt, Daniel Teupser, Rudolf Maria Huber, Jürgen Behr & Nikolaus Kneidinger. (2015) Identification of a novel SERPINA-1 mutation causing alpha-1 antitrypsin deficiency in a patient with severe bronchiectasis and pulmonary embolism. International Journal of Chronic Obstructive Pulmonary Disease 10, pages 891-897.
Read now
Read now
Robert A. Stockley. (2015) Antitrypsin Deficiency Assessment and Programme for Treatment (ADAPT): The United Kingdom Registry. COPD: Journal of Chronic Obstructive Pulmonary Disease 12:sup1, pages 63-68.
Read now
Read now
Ana C. Bradi, Nadeen Audisho, Deborah K. Casey & Kenneth R. Chapman. (2015) Alpha-1 Antitrypsin Deficiency in Canada: Regional Disparities in Diagnosis and Management. COPD: Journal of Chronic Obstructive Pulmonary Disease 12:sup1, pages 15-21.
Read now
Read now
Robert A. Sandhaus, James Stocks, Farshid N. Rouhani, Mark Brantly & Pnina Strauss. (2014) Biochemical Efficacy and Safety of a New, Ready-to-Use, Liquid Alpha-1-Proteinase Inhibitor, GLASSIA (Alpha1-Proteinase Inhibitor (Human), Intravenous). COPD: Journal of Chronic Obstructive Pulmonary Disease 11:1, pages 17-25.
Read now
Read now
Judith A Brebner & Robert A Stockley. (2013) Recent advances in α-1-antitrypsin deficiency-related lung disease. Expert Review of Respiratory Medicine 7:3, pages 213-230.
Read now
Read now
Robert A. Stockley, Asger Dirksen & Jan Stolk. (2013) Alpha-1 Antitrypsin Deficiency: The European Experience. COPD: Journal of Chronic Obstructive Pulmonary Disease 10:sup1, pages 50-53.
Read now
Read now
Xiaobo Li, Na Wei, Zhangjun Wu, Zhanzhong Qi, Xin Zhang, Qiuling Chen, Zhiqiang Xia & Shuo Li. (2012) The D/I Polymorphism in the Angiotensin-Converting Enzyme Gene and Chronic Obstructive Pulmonary Disease Risk: A Meta-Analysis. COPD: Journal of Chronic Obstructive Pulmonary Disease 9:5, pages 485-491.
Read now
Read now
Manish Mohanka, Danai Khemasuwan & James K Stoller. (2012) A review of augmentation therapy for alpha-1 antitrypsin deficiency. Expert Opinion on Biological Therapy 12:6, pages 685-700.
Read now
Read now
Raja T Abboud, Tanya N Nelson, Benjamin Jung & Andre Mattman. (2011) Alpha1-antitrypsin deficiency: a clinical-genetic overview. The Application of Clinical Genetics 4, pages 55-65.
Read now
Read now
Catherine M Greene, Tidi Hassan, Kevin Molloy & Noel G McElvaney. (2011) The role of proteases, endoplasmic reticulum stress and SERPINA1 heterozygosity in lung disease and α-1 anti-trypsin deficiency. Expert Review of Respiratory Medicine 5:3, pages 395-411.
Read now
Read now
F. Kueppers. (2011) The role of augmentation therapy in alpha-1 antitrypsin deficiency. Current Medical Research and Opinion 27:3, pages 579-588.
Read now
Read now
Jennifer A Dickens & David A Lomas. (2011) Why has it been so difficult to prove the efficacy of alpha-1-antitrypsin replacement therapy? Insights from the study of disease pathogenesis. Drug Design, Development and Therapy 5, pages 391-405.
Read now
Read now
Robert A Stockley. (2010) Emerging drugs for alpha-1-antitrypsin deficiency. Expert Opinion on Emerging Drugs 15:4, pages 685-694.
Read now
Read now
Alan F. Barker. (2010) Alpha-1 Antitrypsin Deficiency Identification and Management: It is the Team More than the Genes. COPD: Journal of Chronic Obstructive Pulmonary Disease 7:3, pages 162-163.
Read now
Read now
Kenneth R. Chapman, Robert A. Stockley, Mahlon M. Wilkes & Roberta J. Navickis. (2010) Letter to the Editor Response. COPD: Journal of Chronic Obstructive Pulmonary Disease 7:3, pages 235-236.
Read now
Read now
Cormac McCarthy & Borislav D. Dimitrov. (2010) Augmentation Therapy for Alpha-1 Antitrypsin Deficiency—Not Enough Evidence to Support its Use Yet!. COPD: Journal of Chronic Obstructive Pulmonary Disease 7:3, pages 234-234.
Read now
Read now
Articles from other publishers (103)
Francisco Dasí. (2023) Alpha-1 antitrypsin deficiency. Medicina Clínica.
Crossref
Crossref
Theodore S. Kapellos, Thomas M. Conlon, Ali Önder Yildirim & Mareike Lehmann. (2023) The impact of the immune system on lung injury and regeneration in COPD. European Respiratory Journal 62:4, pages 2300589.
Crossref
Crossref
Leonard Riley, Aryaman Sriram, Mark Brantly & Jorge Lascano. (2023) Testing Patterns and Disparities for Alpha-1 Antitrypsin Deficiency. The American Journal of Medicine 136:10, pages 1011-1017.
Crossref
Crossref
Daniella A. Spittle, Alison Mansfield, Anita Pye, Alice M. Turner & Michael Newnham. (2023) Predicting Lung Function Using Biomarkers in Alpha-1 Antitrypsin Deficiency. Biomedicines 11:7, pages 2001.
Crossref
Crossref
N. A. Karchevskaya, M. S. Kevorkova, E. А. Tarabrin, T. Е. Kallagov, I. U. Ibavov, E. I. Pervakova, A. L. Cherniaev, M. V. Samsonova, M. Sh. Khubutiya & A. G. Chuchalin. (2022) Lung transplantation in a patient with α<sub>1</sub>-antitrypsin deficiency emphysema. PULMONOLOGIYA 32:6, pages 899-905.
Crossref
Crossref
J.-F. Mornex, M. Balduyck, M. Bouchecareilh, A. Cuvelier, R. Epaud, M. Kerjouan, O. Le Rouzic, C. Pison, L. Plantier, M.-C. Pujazon, M. Reynaud-Gaubert, A. Toutain, B. Trumbic, M.-C. Willemin, M. Zysman, O. Brun, M. Campana, F. Chabot, V. Chamouard, M. Dechomet, J. Fauve, B. Girerd, C. Gnakamene, S. Lefrançois, J.-N. Lombard, B. Maitre, C. Maynié-François, A. Moerman, A. Payancé, P. Reix, D. Revel, M.-P. Revel, M. Schuers, P. Terrioux, D. Theron, F. Willersinn, V. Cottin & H. Mal. (2022) Atteinte pulmonaire du déficit en alpha-1 antitrypsine. Recommandations pratiques pour le diagnostic et la prise en charge. Revue des Maladies Respiratoires 39:7, pages 633-656.
Crossref
Crossref
Bruno BALBI, Federica BENINI, Luciano CORDA, Angelo CORSICO, Ilaria FERRAROTTI & Nuccia GATTA. (2022) An Italian expert consensus on the management of alpha1-antitrypsin deficiency: a comprehensive set of algorithms. Panminerva Medica 64:2.
Crossref
Crossref
G. Guarnieri, A. Achille, S. Lococo & A. Vianello. (2022) Pregnancy in Alpha 1 Antitrypsin (AAT) Deficiency and the role of intravenous AAT therapy. Pulmonology 28:4, pages 317-319.
Crossref
Crossref
Annalisa Bianchera, Esraa Alomari & Stefano Bruno. (2022) Augmentation Therapy with Alpha-1 Antitrypsin: Present and Future
of Production, Formulation, and Delivery. Current Medicinal Chemistry 29:3, pages 385-410.
Crossref
Crossref
Kenneth R. Chapman. (2022) If All That You Have Is a Hammer…: Can We Phenotype Our Patients with Chronic Obstructive Pulmonary Disease?. American Journal of Respiratory and Critical Care Medicine 205:3, pages 266-267.
Crossref
Crossref
Robert Andrew Stockley. 2022. Encyclopedia of Respiratory Medicine. Encyclopedia of Respiratory Medicine
675
685
.
Caroline A. Owen. 2022. Encyclopedia of Respiratory Medicine. Encyclopedia of Respiratory Medicine
541
557
.
Timm Greulich & Martina Veith. 2022. Seltene Lungenerkrankungen. Seltene Lungenerkrankungen
495
512
.
Iris G.M. Schouten, Marise J. Kasteleyn, Roula Tsonaka, Robert Bals, Alice C. Turner, Ilaria Ferrarotti, Angelo G. Corsico, Beatriz Lara, Marc Miravitlles, Robert A. Stockley & Jan Stolk. (2021)
Long-term effect of α
1
-antitrypsin augmentation therapy on the decline of FEV
1
in deficient patients: an analysis of the AIR database
. ERJ Open Research 7:3, pages 00194-2021.
Crossref
Crossref
Anna Annunziata, Maurizia Lanza, Antonietta Coppola, Paolo Andreozzi, Sara Spinelli & Giuseppe Fiorentino. (2021) Alpha-1 Antitrypsin Deficiency: Home Therapy. Frontiers in Pharmacology 12.
Crossref
Crossref
Simona Viglio, Elisabeth G. Bak, Iris G. M. Schouten, Paolo Iadarola & Jan Stolk. (2021) Protease-Specific Biomarkers to Analyse Protease Inhibitors for Emphysema Associated with Alpha 1-Antitrypsin Deficiency. An Overview of Current Approaches. International Journal of Molecular Sciences 22:3, pages 1065.
Crossref
Crossref
Igor Barjaktarevic & Michael Campos. (2021) Management of lung disease in alpha-1 antitrypsin deficiency: what we do and what we do not know. Therapeutic Advances in Chronic Disease 12_suppl, pages 204062232110101.
Crossref
Crossref
Jan Sieluk, Julia F. Slejko, Henry Silverman, Eleanor Perfetto & C. Daniel Mullins. (2020) Medical costs of Alpha-1 antitrypsin deficiency-associated COPD in the United States. Orphanet Journal of Rare Diseases 15:1.
Crossref
Crossref
Mark Brantly, Michael Campos, Angela M. Davis, Jeanine D’Armiento, Kenneth Goodman, Kathi Hanna, Miriam O’Day, John Queenan, Robert Sandhaus, James Stoller, Charlie Strange, Jeffrey Teckman & Adam Wanner. (2020) Detection of alpha-1 antitrypsin deficiency: the past, present and future. Orphanet Journal of Rare Diseases 15:1.
Crossref
Crossref
Fernanda Martini, Monica De Mattei, Carlo Contini & Mauro G. Tognon. (2020) Potential Use of Alpha-1 Anti-trypsin in the Covid-19 Treatment. Frontiers in Cell and Developmental Biology 8.
Crossref
Crossref
Kenneth R. Chapman. (2020) Bench to Bedside and Back: The Evolving Story of Alpha-1 Antitrypsin Deficiency. American Journal of Respiratory Cell and Molecular Biology 63:4, pages 403-404.
Crossref
Crossref
Simona Viglio, Paolo Iadarola, Maura D’Amato & Jan Stolk. (2020) Methods of Purification and Application Procedures of Alpha1 Antitrypsin: A Long-Lasting History. Molecules 25:17, pages 4014.
Crossref
Crossref
Roxana Cortes-Lopez & Igor Barjaktarevic. (2020) Alpha-1 Antitrypsin Deficiency: a Rare Disease?. Current Allergy and Asthma Reports 20:9.
Crossref
Crossref
Ahmad Karadagi, Alex G. Cavedon, Helen Zemack, Greg Nowak, Marianne E. Eybye, Xuling Zhu, Eleonora Guadagnin, Rebecca A. White, Lisa M. Rice, Andrea L. Frassetto, Stephen Strom, Carl Jorns, Paolo G. V. Martini & Ewa Ellis. (2020) Systemic modified messenger RNA for replacement therapy in alpha 1-antitrypsin deficiency. Scientific Reports 10:1.
Crossref
Crossref
Mario Cazzola, Daiana Stolz, Paola Rogliani & Maria Gabriella Matera. (2020)
α
1
-Antitrypsin deficiency and chronic respiratory disorders
. European Respiratory Review 29:155, pages 190073.
Crossref
Crossref
Jack Dummer, Claudia C. Dobler, Mark Holmes, Daniel Chambers, Ian A. Yang, Lianne Parkin, Sheree Smith, Peter Wark, Anouk Dev, Sandra Hodge, Eli Dabscheck, Julian Gooi, Sameh Samuel, Steven Knowles & Anne E. Holland. (2020) Diagnosis and treatment of lung disease associated with alpha one‐antitrypsin deficiency: A position statement from the Thoracic Society of Australia and New Zealand*. Respirology 25:3, pages 321-335.
Crossref
Crossref
R. Zapater López, N. Marcos Carrasco, L. Téllez Villajos & J. Martínez González. (2020) Enfermedades hepáticas de causa metabólica. Medicine - Programa de Formación Médica Continuada Acreditado 13:4, pages 191-202.
Crossref
Crossref
Stephan F. van Eeden & James C. Hogg. (2020) Immune-Modulation in Chronic Obstructive Pulmonary Disease: Current Concepts and Future Strategies. Respiration 99:7, pages 550-565.
Crossref
Crossref
Nestor A. Molfino. 2020. Emery and Rimoin's Principles and Practice of Medical Genetics and Genomics. Emery and Rimoin's Principles and Practice of Medical Genetics and Genomics
361
403
.
Franck Rahaghi, Laurel Omert, Virginia Clark & Robert A. Sandhaus. (2019) Managing the Alpha-1 patient in the ICU: Adapting broad critical care strategies in AATD. Journal of Critical Care 54, pages 212-219.
Crossref
Crossref
Sabina Janciauskiene & Tobias Welte. 2019.
α
1
-Antitrypsin Deficiency
.
α
1
-Antitrypsin Deficiency
159
178
.
Michael A. Campos, Patrick Geraghty, Gregory Holt, Eliana Mendes, Paul R. Newby, Shuren Ma, Landy V. Luna-Diaz, Gerard M. Turino & Robert A. Stockley. (2019) The Biological Effects of Double-Dose Alpha-1 Antitrypsin Augmentation Therapy. A Pilot Clinical Trial. American Journal of Respiratory and Critical Care Medicine 200:3, pages 318-326.
Crossref
Crossref
Hannah A. Blair. (2019) Human α1-proteinase inhibitor (Respreeza®) in α1-antitrypsin deficiency emphysema: a profile of its use in the EU. Drugs & Therapy Perspectives 35:8, pages 363-368.
Crossref
Crossref
Paul R. Newby, Diana Crossley, Helena Crisford, James A. Stockley, Richard A. Mumford, Richard I. Carter, Charlotte E. Bolton, Nicholas S. Hopkinson, Ravi Mahadeva, Michael C. Steiner, Tom M.A. Wilkinson, Elizabeth Sapey & Robert A. Stockley. (2019)
A specific proteinase 3 activity footprint in α
1
-antitrypsin deficiency
. ERJ Open Research 5:3, pages 00095-2019.
Crossref
Crossref
Marinos Pericleous, Claire Kelly, Aftab Ala & Michael L. Schilsky. 2019. Clinical Epidemiology of Chronic Liver Diseases. Clinical Epidemiology of Chronic Liver Diseases
307
330
.
María Torres-Durán, José Luis Lopez-Campos, Miriam Barrecheguren, Marc Miravitlles, Beatriz Martinez-Delgado, Silvia Castillo, Amparo Escribano, Adolfo Baloira, María Mercedes Navarro-Garcia, Daniel Pellicer, Lucía Bañuls, María Magallón, Francisco Casas & Francisco Dasí. (2018) Alpha-1 antitrypsin deficiency: outstanding questions and future directions. Orphanet Journal of Rare Diseases 13:1.
Crossref
Crossref
A.P. Lopes, M.A. Mineiro, F. Costa, J. Gomes, C. Santos, C. Antunes, D. Maia, R. Melo, M. Canotilho, E. Magalhães, I. Vicente, C. Valente, B.G. Gonçalves, B. Conde, C. Guimarães, C. Sousa, J. Amado, M.E. Brandão, M. Sucena, M.J. Oliveira, S. Seixas, V. Teixeira & L. Telo. (2018) Portuguese consensus document for the management of alpha-1-antitrypsin deficiency. Pulmonology 24, pages 1-21.
Crossref
Crossref
Timothy J. Craig & Maria Paula Henao. (2018)
Advances in managing COPD related to α
1
-antitrypsin deficiency: An under-recognized genetic disorder
. Allergy 73:11, pages 2110-2121.
Crossref
Crossref
Minsun Kim, Qing Cai & Youngman Oh. (2018) Therapeutic potential of alpha-1 antitrypsin in human disease. Annals of Pediatric Endocrinology & Metabolism 23:3, pages 131-135.
Crossref
Crossref
Article Editorial. (2018) Diagnosis and treatment of pulmonarydisease in α1-antitrypsin deficiency: a statement of European Respiratory Society. Russian Pulmonology 28:3, pages 273-295.
Crossref
Crossref
Sebastian Fähndrich, Nikolas Bernhard, Philipp Lepper & Robert Bals. (2018) Alpha-1-Antitrypsin-Mangel: Pathophysiologie, Diagnostik und Therapie. Pneumo News 10:2, pages 31-40.
Crossref
Crossref
Michael A. Campos, Michael C. Runken, Angela M. Davis, Michael P. Johnson, Glenda A. Stone & Ami R. Buikema. (2018) Impact of a Health Management Program on Healthcare Outcomes among Patients on Augmentation Therapy for Alpha 1-Antitrypsin Deficiency: An Insurance Claims Analysis. Advances in Therapy 35:4, pages 467-481.
Crossref
Crossref
Gabriel Thabut & Luciano Corda. (2018) Epidemiology, Diagnosis and Available Treatment for Alpha 1 Antitrypsin Deficiency-related Emphysema in Europe. European Respiratory & Pulmonary Diseases 4:1, pages 25.
Crossref
Crossref
Franck F. Rahaghi & Marc Miravitlles. (2017) Long-term clinical outcomes following treatment with alpha 1-proteinase inhibitor for COPD associated with alpha-1 antitrypsin deficiency: a look at the evidence. Respiratory Research 18:1.
Crossref
Crossref
Marc Miravitlles, Asger Dirksen, Ilaria Ferrarotti, Vladimir Koblizek, Peter Lange, Ravi Mahadeva, Noel G. McElvaney, David Parr, Eeva Piitulainen, Nicolas Roche, Jan Stolk, Gabriel Thabut, Alice Turner, Claus Vogelmeier & Robert A. Stockley. (2017)
European Respiratory Society statement: diagnosis and treatment of pulmonary disease in α
1
-antitrypsin deficiency
. European Respiratory Journal 50:5, pages 1700610.
Crossref
Crossref
Michael A. Tortorici, James A. Rogers, Oliver Vit, Martin Bexon, Robert A. Sandhaus, Jonathan Burdon, Joanna Chorostowska-Wynimko, Philip Thompson, James Stocks, Noel G. McElvaney, Kenneth R. Chapman & Jonathan M. Edelman. (2017) Quantitative disease progression model of α-1 proteinase inhibitor therapy on computed tomography lung density in patients with α-1 antitrypsin deficiency. British Journal of Clinical Pharmacology 83:11, pages 2386-2397.
Crossref
Crossref
Janet Fricker. (2017) Transitioning Clinical Data into Patient Care: Recent Real-Life Experiences with Alpha 1. EMJ Respiratory, pages 32-40.
Crossref
Crossref
Theodore Kelbel, Darren Morris, Deirdre Walker, Maria Paula Henao & Timothy Craig. (2017) The Allergist's Role in Detection of Severe Alpha-1 Antitrypsin Deficiency. The Journal of Allergy and Clinical Immunology: In Practice 5:5, pages 1302-1306.
Crossref
Crossref
Claus F. Vogelmeier, Gerard J. Criner, Fernando J. Martinez, Antonio Anzueto, Peter J. Barnes, Jean Bourbeau, Bartolome R. Celli, Rongchang Chen, Marc Decramer, Leonardo M. Fabbri, Peter Frith, David M.G. Halpin, M. Victorina López Varela, Masaharu Nishimura, Nicolas Roche, Roberto Rodriguez‐Roisin, Don D. Sin, Dave Singh, Robert Stockley, Jørgen Vestbo, Jadwiga A. Wedzicha & Alvar Agusti. (2017) Global Strategy for the Diagnosis, Management and Prevention of Chronic Obstructive Lung Disease 2017 Report. Respirology 22:3, pages 575-601.
Crossref
Crossref
Scott M. Gordon & Alan T. Remaley. (2017) High density lipoproteins are modulators of protease activity: Implications in inflammation, complement activation, and atherothrombosis. Atherosclerosis 259, pages 104-113.
Crossref
Crossref
Claus F. Vogelmeier, Gerard J. Criner, Fernando J. Martinez, Antonio Anzueto, Peter J. Barnes, Jean Bourbeau, Bartolome R. Celli, Rongchang Chen, Marc Decramer, Leonardo M. Fabbri, Peter Frith, David M.G. Halpin, M. Victorina López Varela, Masaharu Nishimura, Nicolas Roche, Roberto Rodriguez-Roisin, Don D. Sin, Dave Singh, Robert Stockley, Jørgen Vestbo, Jadwiga A. Wedzicha & Alvar Agusti. (2017) Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Lung Disease 2017 Report: GOLD Executive Summary. European Respiratory Journal 49:3, pages 1700214.
Crossref
Crossref
Claus F. Vogelmeier, Gerard J. Criner, Fernando J. Martinez, Antonio Anzueto, Peter J. Barnes, Jean Bourbeau, Bartolome R. Celli, Rongchang Chen, Marc Decramer, Leonardo M. Fabbri, Peter Frith, David M. G. Halpin, M. Victorina López Varela, Masaharu Nishimura, Nicolas Roche, Roberto Rodriguez-Roisin, Don D. Sin, Dave Singh, Robert Stockley, Jørgen Vestbo, Jadwiga A. Wedzicha & Alvar Agustí. (2017) Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Lung Disease 2017 Report. GOLD Executive Summary. American Journal of Respiratory and Critical Care Medicine 195:5, pages 557-582.
Crossref
Crossref
Claus F. Vogelmeier, Gerard J. Criner, Fernando J. Martínez, Antonio Anzueto, Peter J. Barnes, Jean Bourbeau, Bartolome R. Celli, Rongchang Chen, Marc Decramer, Leonardo M. Fabbri, Peter Frith, David M.G. Halpin, M. Victorina López Varela, Masaharu Nishimura, Nicolás Roche, Roberto Rodríguez-Roisin, Don D. Sin, Dave Singh, Robert Stockley, Jørgen Vestbo, Jadwiga A. Wedzicha & Alvar Agustí. (2017) Informe 2017 de la Iniciativa Global para el Diagnóstico, Tratamiento y Prevención de la Enfermedad Pulmonar Obstructiva Crónica: Resumen Ejecutivo de GOLD. Archivos de Bronconeumología 53:3, pages 128-149.
Crossref
Crossref
Claus F. Vogelmeier, Gerard J. Criner, Fernando J. Martinez, Antonio Anzueto, Peter J. Barnes, Jean Bourbeau, Bartolome R. Celli, Rongchang Chen, Marc Decramer, Leonardo M. Fabbri, Peter Frith, David M.G. Halpin, M. Victorina López Varela, Masaharu Nishimura, Nicolas Roche, Roberto Rodriguez-Roisin, Don D. Sin, Dave Singh, Robert Stockley, Jørgen Vestbo, Jadwiga A. Wedzicha & Alvar Agusti. (2017) Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Lung Disease 2017 Report: GOLD Executive Summary. Archivos de Bronconeumología (English Edition) 53:3, pages 128-149.
Crossref
Crossref
Noel G McElvaney, Jonathan Burdon, Mark Holmes, Allan Glanville, Peter A B Wark, Philip J Thompson, Paul Hernandez, Jan Chlumsky, Helmut Teschler, Joachim H Ficker, Niels Seersholm, Alan Altraja, Riitta Mäkitaro, Joanna Chorostowska-Wynimko, Marek Sanak, Paul I Stoicescu, Eeva Piitulainen, Oliver Vit, Marion Wencker, Michael A Tortorici, Michael Fries, Jonathan M Edelman & Kenneth R Chapman. (2017) Long-term efficacy and safety of α1 proteinase inhibitor treatment for emphysema caused by severe α1 antitrypsin deficiency: an open-label extension trial (RAPID-OLE). The Lancet Respiratory Medicine 5:1, pages 51-60.
Crossref
Crossref
Ignacio Blanco. 2017. Blanco's Overview of Alpha-1 Antitrypsin Deficiency. Blanco's Overview of Alpha-1 Antitrypsin Deficiency
175
191
.
Robert Stockley. 2017. Alpha-1-antitrypsin Deficiency. Alpha-1-antitrypsin Deficiency
101
116
.
Michael Campos & Jorge Lascano. 2017. Alpha-1 Antitrypsin Deficiency. Alpha-1 Antitrypsin Deficiency
249
262
.
Kate McKeage & Katherine A. Lyseng-Williamson. (2016) Human α1-proteinase inhibitor (Respreeza®) in α1-antitrypsin deficiency emphysema: a guide to its use in the EU. Drugs & Therapy Perspectives 32:10, pages 422-427.
Crossref
Crossref
Peter C Gøtzsche & Helle Krogh Johansen. (2016) Intravenous alpha-1 antitrypsin augmentation therapy for treating patients with alpha-1 antitrypsin deficiency and lung disease. Cochrane Database of Systematic Reviews 2016:9.
Crossref
Crossref
Cormac McCarthy, Emer P. Reeves & Noel G. McElvaney. (2016) The Role of Neutrophils in Alpha-1 Antitrypsin Deficiency. Annals of the American Thoracic Society 13:Supplement_4, pages S297-S304.
Crossref
Crossref
Jared T. Perrin & Cassie C. Kennedy. (2016) 48-Year-Old Man With Dyspnea on Exertion. Mayo Clinic Proceedings 91:4, pages 509-513.
Crossref
Crossref
Timm Greulich. 2016. Seltene Lungenerkrankungen. Seltene Lungenerkrankungen
369
383
.
Haala K. Rokadia & James K. Stoller. (2015) Surgical and Bronchoscopic Lung Volume Reduction Treatment for α-1 Antitrypsin Deficiency. Clinical Pulmonary Medicine 22:6, pages 279-285.
Crossref
Crossref
C E Green, S Vayalapra, J A Hampson, D Mukherjee, R A Stockley & A M Turner. (2015) PiSZ alpha-1 antitrypsin deficiency (AATD): pulmonary phenotype and prognosis relative to PiZZ AATD and PiMM COPD. Thorax 70:10, pages 939-945.
Crossref
Crossref
Damian Bruce-Hickman, Catherine M. Greene & Bibek Gooptu. 2015. Controversies in COPD. Controversies in COPD
47
84
.
Daniela Giacoboni, Miriam Barrecheguren, Cristina Esquinas, Esther Rodríguez, Cristina Berastegui, Manuel López-Meseguer, Víctor Monforte, Carlos Bravo, Pietro Pirina, Marc Miravitlles & Antonio Román. (2015) Características de la población candidata a trasplante pulmonar por enfermedad pulmonar obstructiva crónica y por enfisema secundario a déficit de alfa 1 antitripsina. Archivos de Bronconeumología 51:8, pages 379-383.
Crossref
Crossref
Daniela Giacoboni, Miriam Barrecheguren, Cristina Esquinas, Esther Rodríguez, Cristina Berastegui, Manuel López-Meseguer, Víctor Monforte, Carlos Bravo, Pietro Pirina, Marc Miravitlles & Antonio Román. (2015) Characteristics of Candidates for Lung Transplantation Due to Chronic Obstructive Pulmonary Disease and Alpha-1 Antitrypsin Deficiency Emphysema. Archivos de Bronconeumología (English Edition) 51:8, pages 379-383.
Crossref
Crossref
Kenneth R Chapman, Jonathan G W Burdon, Eeva Piitulainen, Robert A Sandhaus, Niels Seersholm, James M Stocks, Berend C Stoel, Liping Huang, Zhenling Yao, Jonathan M Edelman & Noel G McElvaney. (2015) Intravenous augmentation treatment and lung density in severe α1 antitrypsin deficiency (RAPID): a randomised, double-blind, placebo-controlled trial. The Lancet 386:9991, pages 360-368.
Crossref
Crossref
Francisco Casas, Ignacio Blanco, María Teresa Martínez, Ana Bustamante, Marc Miravitlles, Sergio Cadenas, José M. Hernández, Lourdes Lázaro, Esther Rodríguez, Francisco Rodríguez-Frías, María Torres & Beatriz Lara. (2015) Actualización sobre indicaciones de búsqueda activa de casos y tratamiento con alfa-1 antitripsina por vía intravenosa en pacientes con enfermedad pulmonar obstructiva crónica asociada a déficit de alfa-1 antitripsina. Archivos de Bronconeumología 51:4, pages 185-192.
Crossref
Crossref
Francisco Casas, Ignacio Blanco, María Teresa Martínez, Ana Bustamante, Marc Miravitlles, Sergio Cadenas, José M. Hernández, Lourdes Lázaro, Esther Rodríguez, Francisco Rodríguez-Frías, María Torres & Beatriz Lara. (2015) Indications for Active Case Searches and Intravenous Alpha-1 Antitrypsin Treatment for Patients With Alpha-1 Antitrypsin Deficiency Chronic Pulmonary Obstructive Disease: An Update. Archivos de Bronconeumología (English Edition) 51:4, pages 185-192.
Crossref
Crossref
Helmut Teschler. (2015)
Long-term experience in the treatment of α
1
-antitrypsin deficiency: 25 years of augmentation therapy
. European Respiratory Review 24:135, pages 46-51.
Crossref
Crossref
Michael A. Campos & Jorge Lascano. (2014) α1 Antitrypsin deficiency: current best practice in testing and augmentation therapy. Therapeutic Advances in Respiratory Disease 8:5, pages 150-161.
Crossref
Crossref
F. de Serres & I. Blanco. (2014) Role of alpha-1 antitrypsin in human health and disease. Journal of Internal Medicine 276:4, pages 311-335.
Crossref
Crossref
Cormac McCarthy, Radka Saldova, Mark R WormaldPauline M. Rudd, Noel G. McElvaney & Emer P. Reeves. (2014) The Role and Importance of Glycosylation of Acute Phase Proteins with Focus on Alpha-1 Antitrypsin in Acute and Chronic Inflammatory Conditions. Journal of Proteome Research 13:7, pages 3131-3143.
Crossref
Crossref
Anilkumar P. Pillai, Alice M. Turner & Robert A. Stockley. (2014)
Relationship of the 2011 Global Initiative for Chronic Obstructive Lung Disease Strategy to Clinically Relevant Outcomes in Individuals with α
1
-Antitrypsin Deficiency
. Annals of the American Thoracic Society 11:6, pages 859-864.
Crossref
Crossref
Robert A. Stockley. (2014) Alpha1-antitrypsin Review. Clinics in Chest Medicine 35:1, pages 39-50.
Crossref
Crossref
Robert A. Stockley & Alice M. Turner. (2014) α-1-Antitrypsin deficiency: clinical variability, assessment, and treatment. Trends in Molecular Medicine 20:2, pages 105-115.
Crossref
Crossref
Robert A. Stockley. (2013) α 1 -Antitrypsin Deficiency. Chest 144:6, pages 1923-1929.
Crossref
Crossref
F. Lebargy. (2013) Les 50 ans de la découverte du déficit en alpha-1 antitrypsine. Revue des Maladies Respiratoires Actualités 5:6, pages 607-611.
Crossref
Crossref
Alice M. Turner. (2013) Alpha-1 Antitrypsin Deficiency: New Developments in Augmentation and Other Therapies. BioDrugs 27:6, pages 547-558.
Crossref
Crossref
Anilkumar P. Pillai, Alice M. Turner & Robert A. Stockley. (2013) Global Initiative for Chronic Obstructive Lung Disease 2011 Symptom/Risk Assessment in α 1 -Antitrypsin Deficiency. Chest 144:4, pages 1152-1162.
Crossref
Crossref
Timm Greulich, Stefania Ottaviani, Robert Bals, Philipp M. Lepper, Claus Vogelmeier, Maurizio Luisetti & Ilaria Ferrarotti. (2013) Alpha1-antitrypsin deficiency – Diagnostic testing and disease awareness in Germany and Italy. Respiratory Medicine 107:9, pages 1400-1408.
Crossref
Crossref
Alice M. Turner. (2013) Fifty Years On: GWAS Confirms the Role of a Rare Variant in Lung Disease. PLoS Genetics 9:8, pages e1003768.
Crossref
Crossref
Kim Hoenderdos & Alison Condliffe. (2013) The Neutrophil in Chronic Obstructive Pulmonary Disease. Too Little, Too Late or Too Much, Too Soon?. American Journal of Respiratory Cell and Molecular Biology 48:5, pages 531-539.
Crossref
Crossref
Bruce C Trapnell & Maurizio Luisetti. (2013) The parallel lives of alpha1-antitrypsin deficiency and pulmonary alveolar proteinosis. Orphanet Journal of Rare Diseases 8:1, pages 153.
Crossref
Crossref
Robert A Stockley, Marc Miravitlles & Claus Vogelmeier. (2013) Augmentation therapy for alpha-1 antitrypsin deficiency: towards a personalised approach. Orphanet Journal of Rare Diseases 8:1, pages 149.
Crossref
Crossref
Chad K. Oh & Nestor A. Molfino. 2013. Emery and Rimoin's Principles and Practice of Medical Genetics. Emery and Rimoin's Principles and Practice of Medical Genetics
1
33
.
D.W. Cox. 2013. Brenner's Encyclopedia of Genetics. Brenner's Encyclopedia of Genetics
85
87
.
Marilyn G. Foreman, Michael Campos & Juan C. Celedón. (2012) Genes and Chronic Obstructive Pulmonary Disease. Medical Clinics of North America 96:4, pages 699-711.
Crossref
Crossref
Michael Campos, Diego Shmuels & John Walsh. (2012) Detection of Alpha-1 Antitrypsin Deficiency in the US. The American Journal of Medicine 125:7, pages 623-624.
Crossref
Crossref
Maureen M. J. Guichelaar & Michael R. Charlton. 2012. Medical Care of the Liver Transplant Patient. Medical Care of the Liver Transplant Patient
97
109
.
Juan Carlos Barros-Tizón, María Luisa Torres, Ignacio Blanco & María Teresa Martínez. (2012) Reduction of severe exacerbations and hospitalization-derived costs in alpha-1-antitrypsin-deficient patients treated with alpha-1-antitrypsin augmentation therapy. Therapeutic Advances in Respiratory Disease 6:2, pages 67-78.
Crossref
Crossref
David A. Bergin, Killian Hurley, Noel G. McElvaney & Emer P. Reeves. (2012) Alpha-1 Antitrypsin: A Potent Anti-Inflammatory and Potential Novel Therapeutic Agent. Archivum Immunologiae et Therapiae Experimentalis 60:2, pages 81-97.
Crossref
Crossref
James K. Stoller & Loutfi S. Aboussouan. (2012)
A Review of α
1
-Antitrypsin Deficiency
. American Journal of Respiratory and Critical Care Medicine 185:3, pages 246-259.
Crossref
Crossref
Moshe Zutler, Patricia J Quinlan & Paul D Blanc. (2011) Alpha-1-antitrypsin deficient man presenting with lung function decline associated with dust exposure: a case report. Journal of Medical Case Reports 5:1.
Crossref
Crossref
Frank Tacke & Christian Trautwein. (2011) Controlling autophagy: A new concept for clearing liver disease. Hepatology 53:1, pages 356-358.
Crossref
Crossref
R. Siekmeier. (2010) Lung deposition of inhaled Alpha-1-proteinase inhibitor (Alpha1-PI) - problems and experience of Alpha1-PI inhalation therapy in patients with hereditary Alpha1-PI deficiency and cystic fibrosis. European Journal of Medical Research 15:S2.
Crossref
Crossref
James M Stocks, Mark L Brantly, Laurene Wang-Smith, Michael A Campos, Kenneth R Chapman, Friedrich Kueppers, Robert A Sandhaus, Charlie Strange & Gerard Turino. (2010) Pharmacokinetic comparability of Prolastin®-C to Prolastin® in alpha1-antitrypsin deficiency: a randomized study. BMC Clinical Pharmacology 10:1.
Crossref
Crossref
Adriano R. Tonelli & Mark L. Brantly. (2010) Augmentation therapy in alpha-1 antitrypsin deficiency: advances and controversies. Therapeutic Advances in Respiratory Disease 4:5, pages 289-312.
Crossref
Crossref
Peter C Gøtzsche & Helle Krogh Johansen. 1996. Cochrane Database of Systematic Reviews. Cochrane Database of Systematic Reviews.
Theodore G. Liou, Eric P. Elkin, David J. Pasta, Joan R. Jacobs, Michael W. Konstan, Wayne J. Morgan & Jeffrey S. Wagener. (2010) Year-to-year changes in lung function in individuals with cystic fibrosis. Journal of Cystic Fibrosis 9:4, pages 250-256.
Crossref
Crossref
. (2009)
Alpha
1
-Antitrypsin Deficiency
. New England Journal of Medicine 361:21, pages 2101-2102.
Crossref
Crossref